Fig. 2From: Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United StatesTornado diagram of univariant sensitivity analyses German model. GDP = gross domestic product per capita; LY = life years; QALY = quality-adjusted life years; BSC = best supportive careBack to article page